Supportive Care: Infection Disease Prophylaxis and Advice for Community Doctors

Opinion
Video

Panelists discuss the essential role of supportive care following chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma, emphasizing infection prevention through prophylaxis, immunoglobulin replacement, and vaccination strategies, along with the importance of coordinated long-term management between CAR T centers and community oncologists to ensure sustained survivorship care.

Supportive care is a critical component of managing patients after CAR T-cell therapy, especially given the elevated risk of infections in the first year post treatment. Prophylactic strategies are essential to mitigate nonrelapse mortality, which is often driven by infection rather than disease progression. Standard practice includes antiviral (eg, acyclovir) and Pneumocystis prophylaxis (eg, trimethoprim/sulfamethoxazole [Bactrim]) for at least 6 months, often extended based on immune reconstitution markers like CD4 counts. Immunoglobulin replacement with intravenous immunoglobulin is frequently initiated as a primary preventive measure, targeting immunoglobulin G levels above 400 mg/dL, with adjustments made for patients experiencing recurrent or severe infections.

Vaccination strategies are evolving in response to increasing survivorship. Many centers now reinitiate childhood vaccinations approximately 6 months after CAR T-cell infusion, mirroring autologous transplant protocols. However, with increasing awareness of waning immunity, some institutions are checking vaccine titers and recommending revaccination for a broader set of antigens, including measles, mumps, and rubella, if titers are low and the patient’s immune function has recovered. Respiratory infection prevention, especially during winter months, and antifungal prophylaxis in patients receiving steroids or with prolonged neutropenia, are also key parts of posttreatment care.

Close collaboration between tertiary CAR T centers and community oncologists is essential. Although patients may receive CAR T therapy in specialized centers, long-term infection risk management often shifts to community providers. Clear communication about the need for individualized prophylaxis, immune monitoring, and vaccination schedules ensures that care is not disrupted after patients transition back. With more patients surviving longer following CAR T-cell therapy, these supportive measures are becoming foundational to survivorship care in relapsed/refractory myeloma.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Symposiums and regional meetings may expand knowledge of how to adopt novel CAR T-cell therapies and bispecific antibodies, said Suman Kambhampati, MD.
Related Content